TMEM16A Antagonism: Therapeutic Potential with Desensitization of β-Agonist Responsiveness in Asthma
- 1 May 2025
- journal article
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 72 (5) , 510-519
Abstract
The efficacy of β-agonists in asthma is severely limited by β-adrenoceptor desensitization, which results in poorly managed symptoms and refractory bronchoconstriction. Thus, there is a need to identify novel therapeutic pathways and to clarify the relationship between novel therapeutics and functional β-adrenoceptor responsiveness. We have previously demonstrated that acute antagonism of the calcium-activated chloride channel, transmembrane member 16A (TMEM16A), relaxes airway smooth muscle (ASM). We sought to determine the efficacy and role of TMEM16A antagonism in the context of desensitization β-adrenoceptor responsiveness. For these studies, we exposed murine tracheal rings on wire myography and precision-cut lung slices to contractile mediators in the presence or absence of TMEM16A antagonists and β-agonists with or without prior β-adrenoceptor desensitization. Contractile studies were also performed with human tracheal and bronchial ASM. Finally, the ability of TMEM16A antagonism to prevent desensitization of β2-adrenoceptor–induced cAMP synthesis was measured in human ASM cells. From these studies, we demonstrate that acute TMEM16A antagonism is effective in relaxing β-agonist–desensitized ASM in central and peripheral murine ASM and human ASM. Furthermore, we demonstrate that chronic pretreatment with TMEM16A antagonists prevents functional desensitization of β-agonist responsiveness in mouse and human upper airways and prevents desensitization of β-agonist–mediated cAMP production in human ASM cells. Taken together, the present study demonstrates a favorable therapeutic profile of TMEM16A antagonism for ASM relaxation despite functional desensitization of β-agonist responsiveness, which may be a novel therapeutic approach in the face of β-adrenoceptor tachyphylaxis.Keywords
Funding Information
- NIH (HL132203)
- NIH (HL122340)
- NIH (GM065281)
- NIH (HL132203)
- NIH (HL122340)
- NIH (GM065281)
This publication has 51 references indexed in Scilit:
- Niclosamide, but not ivermectin, inhibits anoctamin 1 and 6 and attenuates inflammation of the respiratory tractPflügers Archiv - European Journal of Physiology, 2023
- Associations of Early-Life Exposure to Submicron Particulate Matter With Childhood Asthma and Wheeze in ChinaJAMA Network Open, 2022
- Asthma-Related Health Outcomes Associated with Short-Acting β2-Agonist Inhaler Use: An Observational UK Study as Part of the SABINA Global ProgramAdvances in Therapy, 2020
- Calcium-activated chloride channels anoctamin 1 and 2 promote murine uterine smooth muscle contractilityAmerican Journal of Obstetrics and Gynecology, 2014
- Novel 5-substituted benzyloxy-2-arylbenzofuran-3-carboxylic acids as calcium activated chloride channel inhibitorsBioorganic & Medicinal Chemistry, 2012
- Steroids completely reverse albuterol-induced β2-adrenergic receptor tolerance in human small airwaysJournal of Allergy and Clinical Immunology, 2008
- β-Adrenoceptor responses of the airways: For better or worse?European Journal of Pharmacology, 2006
- Desensitization of the β-adrenergic recepton: Distinct molecular determinants of phosphorylation by specific kinasesPharmacological Research, 1991
- Regular inhaled beta-agonist treatment in bronchial asthmaThe Lancet, 1990
- Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: A comparison between budesonide and terbutalineJournal of Allergy and Clinical Immunology, 1985